Terms: = Leukemia AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Treatment
2182 results:
1.
Santini V; Stahl M; Sallman DA
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432650. PubMed ID: 38768424
[No Abstract] [Full Text] [Related]
2. On the mechanism of wogonin against acute monocytic leukemia using network pharmacology and experimental validation.
Wang X; Wang Y; Chen J; Wang Q; Liu Z; Yin Y; Yang T; Shen T; Sa Y
Sci Rep; 2024 May; 14(1):10114. PubMed ID: 38698063
[TBL] [Abstract] [Full Text] [Related]
3. Cytogenetic abnormalities and tp53 and RAS gene profiles of childhood acute lymphoblastic leukemia in Morocco.
Skhoun H; El Fessikh M; El Alaoui Al Abdallaoui M; Khattab M; Belkhayat A; Chebihi ZT; Hassani A; Abilkassem R; Agadr A; Dakka N; El Baghdadi J
Arch Pediatr; 2024 May; 31(4):238-244. PubMed ID: 38679547
[TBL] [Abstract] [Full Text] [Related]
4. Putting the STING back into BH3-mimetic drugs for tp53-mutant blood cancers.
Diepstraten ST; Yuan Y; La Marca JE; Young S; Chang C; Whelan L; Ross AM; Fischer KC; Pomilio G; Morris R; Georgiou A; Litalien V; Brown FC; Roberts AW; Strasser A; Wei AH; Kelly GL
Cancer Cell; 2024 May; 42(5):850-868.e9. PubMed ID: 38670091
[TBL] [Abstract] [Full Text] [Related]
5. Myelodysplastic Neoplasms (MDS): The Current and Future treatment Landscape.
Karel D; Valburg C; Woddor N; Nava VE; Aggarwal A
Curr Oncol; 2024 Apr; 31(4):1971-1993. PubMed ID: 38668051
[TBL] [Abstract] [Full Text] [Related]
6. Chronic Lymphocytic leukemia/Small Lymphocytic Lymphoma, Version 2.2024.
Wierda WG; Brown J; Abramson JS; Awan F; Bilgrami SF; Bociek G; Brander D; Cortese M; Cripe L; Davis RS; Eradat H; Fakhri B; Fletcher CD; Gaballa S; Hamid MS; Hill B; Kaesberg P; Kahl B; Kamdar M; Kipps TJ; Ma S; Mosse C; Nakhoda S; Parikh S; Schorr A; Schuster S; Seshadri M; Siddiqi T; Stephens DM; Thompson M; Ujjani C; Valdez R; Wagner-Johnston N; Woyach JA; Sundar H; Dwyer M
J Natl Compr Canc Netw; 2024 Apr; 22(3):175-204. PubMed ID: 38626800
[TBL] [Abstract] [Full Text] [Related]
7. Novel PIKfyve/Tubulin Dual-target Inhibitor as a Promising Therapeutic Strategy for B-cell Acute Lymphoblastic leukemia.
Lu Z; Lai Q; Li ZF; Zhong MY; Jiang YL; Feng LY; Zha J; Yao JW; Li Y; Deng XM; Xu B
Curr Med Sci; 2024 Apr; 44(2):298-308. PubMed ID: 38619682
[TBL] [Abstract] [Full Text] [Related]
8. Preparation and Evaluation of Chitosan Coated PLGA Nanoparticles Encapsulating Ivosidenib with Enhanced Cytotoxicity Against Human Liver Cancer Cells.
Alsulays BB; Aodah AH; Ahmed MM; Anwer MK
Int J Nanomedicine; 2024; 19():3461-3473. PubMed ID: 38617799
[TBL] [Abstract] [Full Text] [Related]
9. Design, Synthesis, and Anti-Leukemic Evaluation of a Series of Dianilinopyrimidines by Regulating the Ras/Raf/MEK/ERK and STAT3/c-Myc Pathways.
Wang C; Wang B; Mou Y; Liu X; Chen Q; Pu W; Rao Q; Wang C; Song J; Huang Y; Yan L; Huang L; Li Y
Molecules; 2024 Apr; 29(7):. PubMed ID: 38611876
[TBL] [Abstract] [Full Text] [Related]
10. Discovery of novel co-degradation CK1α and CDK7/9 PROTACs with p53 activation for treating acute myeloid leukemia.
Wang K; Jiang M; Liu H; Meng C; Li M; Lu H
Bioorg Chem; 2024 Jun; 147():107319. PubMed ID: 38593529
[TBL] [Abstract] [Full Text] [Related]
11. Unlocking the potential: A novel prognostic index signature for acute myeloid leukemia.
Zhang LQ; Liang YC; Wang JX; Zhang J; La T; Li QZ
Comput Biol Med; 2024 May; 173():108396. PubMed ID: 38574529
[TBL] [Abstract] [Full Text] [Related]
12. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
Hampel PJ; Swaminathan M; Rogers KA; Parry EM; Burger JA; Davids MS; Ding W; Ferrajoli A; Hyak JM; Jain N; Kenderian SS; Wang Y; Wierda WG; Woyach JA; Parikh SA; Thompson PA
Blood Adv; 2024 May; 8(10):2342-2350. PubMed ID: 38537065
[TBL] [Abstract] [Full Text] [Related]
13. [Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation in the treatment of secondary acute myeloid leukemia].
Yuan XL; Wu YB; Song XL; Chen Y; Lu Y; Lai XY; Shi JM; Liu LZ; Zhao YM; Yu J; Yang LX; Lan JP; Cai Z; Huang H; Luo Y
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):41-47. PubMed ID: 38527837
[No Abstract] [Full Text] [Related]
14. Astaxanthin targets IL-6 and alleviates the LPS-induced adverse inflammatory response of macrophages.
Wu Y; Bashir MA; Shao C; Wang H; Zhu J; Huang Q
Food Funct; 2024 Apr; 15(8):4207-4222. PubMed ID: 38512055
[TBL] [Abstract] [Full Text] [Related]
15. Azacitidine combined with venetoclax alleviates AML-MR with tp53 mutation in SDS: a case report and literature review.
Ma C; Lang H; Chen Y; Yang L; Wang C; Han L; Chen X; Ma W
Anticancer Drugs; 2024 Jul; 35(6):548-555. PubMed ID: 38502829
[TBL] [Abstract] [Full Text] [Related]
16. ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells.
Valdez BC; Yuan B; Murray D; Ramdial JL; Popat U; Nieto Y; Andersson BS
Oncotarget; 2024 Mar; 15():220-231. PubMed ID: 38484153
[TBL] [Abstract] [Full Text] [Related]
17. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial.
Kater AP; Arslan Ö; Demirkan F; Herishanu Y; Ferhanoglu B; Diaz MG; Leber B; Montillo M; Panayiotidis P; Rossi D; Skarbnik A; Tempescul A; Turgut M; Mellink CH; van der Kevie-Kersemaekers AF; Lanham S; Sale B; Del Rio L; Popovic R; Chyla BJ; Busman T; Komlosi V; Wang X; Sail K; Pena GE; Vizkelety T; Forconi F
Lancet Oncol; 2024 Apr; 25(4):463-473. PubMed ID: 38467131
[TBL] [Abstract] [Full Text] [Related]
18. Inotuzumab in Older Patients with Newly Diagnosed Acute Lymphoblastic leukemia-A Podcast.
Jabbour EJ; Stelljes M
Target Oncol; 2024 Mar; 19(2):135-141. PubMed ID: 38457052
[TBL] [Abstract] [Full Text] [Related]
19. Fisetin nanoparticles based on cells cycle and apoptosis intervention for the treatment of lymphoma and leukemia.
Yang T; Gou H; Lin T; Yang Y; Jin X; Dong T; Zhang Y; Chen X
Int J Pharm; 2024 Apr; 654():123971. PubMed ID: 38452832
[TBL] [Abstract] [Full Text] [Related]
20. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study.
Bazinet A; Garcia-Manero G; Short N; Alvarado Y; Bataller A; Abuasab T; Islam R; Montalbano K; Issa G; Maiti A; Yilmaz M; Jain N; Masarova L; Kornblau S; Jabbour E; Montalban-Bravo G; Rausch CR; Pierce S; DiNardo CD; Kadia T; Daver N; Konopleva M; Huang X; Kantarjian H; Ravandi F
Lancet Haematol; 2024 Apr; 11(4):e276-e286. PubMed ID: 38452788
[TBL] [Abstract] [Full Text] [Related]
[Next]